Literature DB >> 12171954

Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users.

C J Hawkey1, I Wilson, J Naesdal, G Långström, A J Swannell, N D Yeomans.   

Abstract

BACKGROUND AND AIMS: Factors predisposing to endoscopic ulcer formation or healing with non-steroidal anti-inflammatory drugs (NSAIDs) have not been well defined.
METHODS: We used multivariate analysis of data from three large similar trials to identify factors associated with endoscopic lesions and healing. We compared the effectiveness of omeprazole 20 mg and 40 mg daily, misoprostol 200 micro g four times daily, and ranitidine 150 mg twice daily in healing ulcers and erosions at different sites and in patients who were Helicobacter pylori positive and negative.
RESULTS: Older age, past ulcer history, rheumatoid arthritis, and H pylori infection were significantly associated with ulcers. Duodenal ulcer was significantly more likely than gastric ulcer with a past ulcer history (odds ratio 1.59, 1.16-2.17), H pylori infection (1.4, 1.04-1.92), and male sex (2.35, 1.75-3.16) while female sex, older age (> or = 60 years: 1.39, 1.03-1.88), and higher NSAID dose (>1 defined daily dose: 1.57, 1.16-2.14) were associated with gastric ulceration. Sex differences were seen in both H pylori positive and negative patients. Gastric and duodenal ulcer healing was significantly faster with omeprazole 20 mg than with misoprostol 200 micro g four times daily or ranitidine 150 mg twice daily although misoprostol was more effective at healing erosions. Gastric ulcer healing was slower with large ulcers (0.37, 0.25-0.54 for >10 mm v 5-10 mm) or a past ulcer history (0.51, 0.34-0.76), and faster with H pylori infection (1.55, 1.06-2.29), especially with acid suppression (72% v 37% at four weeks with ranitidine).
CONCLUSIONS: Among NSAID users, H pylori and male sex independently increase the likelihood of duodenal ulceration. H pylori infection does not affect duodenal ulcer healing and enhances gastric ulcer healing by ranitidine and possibly other acid suppressing treatments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171954      PMCID: PMC1773338          DOI: 10.1136/gut.51.3.344

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  40 in total

1.  Stilboestrol, phenobarbitone, and diet in chronic duodenal ulcer. A factorial therapeutic trial.

Authors:  S C TRUELOVE
Journal:  Br Med J       Date:  1960-08-20

2.  Effects of inhibitors of arachidonic acid metabolism on Paf-induced gastric mucosal necrosis and haemoconcentration.

Authors:  J L Wallace; B J Whittle
Journal:  Br J Pharmacol       Date:  1986-10       Impact factor: 8.739

3.  Sex differences in duodenal ulcer.

Authors: 
Journal:  Br Med J       Date:  1979-03-10

4.  Upper gastrointestinal disease in rheumatoid arthritis.

Authors:  D C Sun; S H Roth; C S Mitchell; D W Englund
Journal:  Am J Dig Dis       Date:  1974-05

Review 5.  Myofibroblasts. II. Intestinal subepithelial myofibroblasts.

Authors:  D W Powell; R C Mifflin; J D Valentich; S E Crowe; J I Saada; A B West
Journal:  Am J Physiol       Date:  1999-08

6.  A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.

Authors:  N D Yeomans; Z Tulassay; L Juhász; I Rácz; J M Howard; C J van Rensburg; A J Swannell; C J Hawkey
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

7.  Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

Authors:  C J Hawkey; J A Karrasch; L Szczepañski; D G Walker; A Barkun; A J Swannell; N D Yeomans
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

8.  Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models.

Authors:  J F Fries; C A Williams; D A Bloch; B A Michel
Journal:  Am J Med       Date:  1991-09       Impact factor: 4.965

9.  Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat.

Authors:  B J Whittle
Journal:  Gastroenterology       Date:  1981-01       Impact factor: 22.682

10.  Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.

Authors:  S E Gabriel; L Jaakkimainen; C Bombardier
Journal:  Ann Intern Med       Date:  1991-11-15       Impact factor: 25.391

View more
  14 in total

1.  Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan.

Authors:  Kae Sugawara; Shigeto Koizumi; Yohei Horikawa; Nobuya Mimori; Tsuyotoshi Tsuji; Hajime Ishii; Shusei Fujimori; Kengo Onochi; Hiroyuki Watanabe; Katsunori Iijima
Journal:  J Gastroenterol       Date:  2019-04-29       Impact factor: 7.527

2.  Gastric acid secretion level modulates the association between Helicobacter pylori infection and low-dose aspirin-induced gastropathy.

Authors:  Katsunori Iijima; Nobuyuki Ara; Yasuhiko Abe; Tomoyuki Koike; Wataru Iwai; Kaname Uno; Naoki Asano; Akira Imatani; Shuichi Ohara; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2011-02-26       Impact factor: 7.527

3.  Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs.

Authors:  C J Hawkey; J Naesdal; I Wilson; G Långström; A J Swannell; R A Peacock; N D Yeomans
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 4.  Diagnostic methods for Helicobacter pylori detection and eradication.

Authors:  A F Goddard; R P H Logan
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

5.  Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies.

Authors:  Dominick J Angiolillo; Catherine Datto; Shane Raines; Neville D Yeomans
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

6.  Prevalence of peptic ulcer in dyspeptic patients and the influence of age, sex, and Helicobacter pylori infection.

Authors:  Hui-Chao Wu; Bi-Guang Tuo; Wei-Min Wu; Yuan Gao; Qing-Qing Xu; Kui Zhao
Journal:  Dig Dis Sci       Date:  2008-02-13       Impact factor: 3.199

7.  Oral and nasal administration of chicken type II collagen suppresses adjuvant arthritis in rats with intestinal lesions induced by meloxicam.

Authors:  Yong-Qiu Zheng; Wei Wei; Yu-Xian Shen; Min Dai; Li-Hua Liu
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

8.  Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study.

Authors:  Aleksandra Sokic-Milutinovic; Miodrag Krstic; Brigita Rozer-Smolovic; Tamara Alempijevic
Journal:  Dig Dis Sci       Date:  2010-01-22       Impact factor: 3.199

9.  Gender-specific protection of estrogen against gastric acid-induced duodenal injury: stimulation of duodenal mucosal bicarbonate secretion.

Authors:  Anders Smith; Cheyanne Contreras; Kwang Hyun Ko; Jimmy Chow; Xiao Dong; Biguang Tuo; Hong-hai Zhang; Dong-bao Chen; Hui Dong
Journal:  Endocrinology       Date:  2008-05-22       Impact factor: 4.736

Review 10.  Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights.

Authors:  Carlos Sostres; Carla Jerusalen Gargallo; Angel Lanas
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.